[Myocardial accumulation of 99mTc MDP in patients subjected to extended adriblastin treatment. Protective effect of strophanthin and vitamin E].
Myocardioscintigraphy with 99mTc MDP is patients undergoing protracted treatment with adriblastin led to the discovery that accumulation of the isotope was infrequent in subjects protected with strophanthin and vitamin E, contrary to the position in an earlier series for whom no treatment designed to reduce the cardiotoxic effect of the antiblastic drug had been provided.
D001943:Breast Neoplasms / Q000188:drug therapy; D004164:Diphosphonates; D004317:Doxorubicin / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013328:Strophanthins / Q000494:pharmacology*; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D014810:Vitamin E / Q000494:pharmacology*
D004164:Diphosphonates; D013328:Strophanthins; D014810:Vitamin E; D013667:Technetium; D004317:Doxorubicin; D013669:Technetium Tc 99m Medronate
Accumulo miocardico del 99mTc MDP in pazienti sottoposti a prolungato trattamento con adriblastina. Azione protettiva della strofantina e della vitamina E.